OPKO Health Inc
OPK1.195USD
+0.005+0.42%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
931.84MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über OPKO Health Inc Unternehmen
OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company focuses on leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies. Its segments include pharmaceutical and diagnostics. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, Rayaldee product sales and its pharmaceutical research and development. The diagnostics segment primarily consists of point-of-care operations. Its pharmaceutical business features Rayaldee, a United States Food and Drug Administration (FDA) approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage three or four chronic kidney disease (CKD) and vitamin D insufficiency, and Somatrogon (hGH-CTP), a once-weekly human growth hormone injection. Its NGENLA (somatrogon-ghla), is a once-weekly, human growth hormone analog indicated for treatment of pediatric patients aged three years and older.
Unternehmensinformationen
BörsenkürzelOPK
Name des UnternehmensOPKO Health Inc
IPO-datumNov 02, 1995
CEODr. Tony F. Cruz, Ph.D.
Anzahl der mitarbeiter2997
WertpapierartOrdinary Share
GeschäftsjahresendeNov 02
Addresse- -
Stadt- -
BörseNASDAQ Global Select Consolidated
Land- -
Postleitzahl- -
Telefon- -
Website- -
BörsenkürzelOPK
IPO-datumNov 02, 1995
CEODr. Tony F. Cruz, Ph.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Jane H. Hsiao, Ph.D.
Dr. Jane H. Hsiao, Ph.D.
Vice Chairman of the Board, Chief Technical Officer
Vice Chairman of the Board, Chief Technical Officer
33.13M
--
Mr. Steven D. (Steve) Rubin, Esq., J.D.
Mr. Steven D. (Steve) Rubin, Esq., J.D.
Executive Vice President - Administration, Director
Executive Vice President - Administration, Director
6.19M
-6.60%
Mr. John A. Paganelli
Mr. John A. Paganelli
Independent Director
Independent Director
393.51K
--
Mr. Adam E. Logal
Mr. Adam E. Logal
Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer
Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer
179.16K
-70.95%
Dr. Richard M. Krasno, Ph.D.
Dr. Richard M. Krasno, Ph.D.
Independent Director
Independent Director
103.33K
--
Dr. Elias A. Zerhouni, M.D.
Dr. Elias A. Zerhouni, M.D.
President, Vice Chairman of the Board
President, Vice Chairman of the Board
89.60K
-84.80%
Dr. Alice Lin-Tsing Yu, M.D., Ph.D.
Dr. Alice Lin-Tsing Yu, M.D., Ph.D.
Independent Director
Independent Director
66.49K
--
Mr. Richard C. (Rick) Pfenniger, Jr.
Mr. Richard C. (Rick) Pfenniger, Jr.
Independent Director
Independent Director
--
--
Dr. Tony F. Cruz, Ph.D.
Dr. Tony F. Cruz, Ph.D.
Chief Executive Officer, Transition Therapeutics, Inc
Chief Executive Officer, Transition Therapeutics, Inc
--
--
Dr. Roger J. Medel, M.D.
Dr. Roger J. Medel, M.D.
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Jane H. Hsiao, Ph.D.
Dr. Jane H. Hsiao, Ph.D.
Vice Chairman of the Board, Chief Technical Officer
Vice Chairman of the Board, Chief Technical Officer
33.13M
--
Mr. Steven D. (Steve) Rubin, Esq., J.D.
Mr. Steven D. (Steve) Rubin, Esq., J.D.
Executive Vice President - Administration, Director
Executive Vice President - Administration, Director
6.19M
-6.60%
Mr. John A. Paganelli
Mr. John A. Paganelli
Independent Director
Independent Director
393.51K
--
Mr. Adam E. Logal
Mr. Adam E. Logal
Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer
Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer
179.16K
-70.95%
Dr. Richard M. Krasno, Ph.D.
Dr. Richard M. Krasno, Ph.D.
Independent Director
Independent Director
103.33K
--
Dr. Elias A. Zerhouni, M.D.
Dr. Elias A. Zerhouni, M.D.
President, Vice Chairman of the Board
President, Vice Chairman of the Board
89.60K
-84.80%
Umsatzaufteilung
Währung: USDAktualisiert: Sun, Jul 6
Währung: USDAktualisiert: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Keine Daten
Nach RegionUSD
Name
Umsatz
Anteil
United States
116.21M
77.50%
Chile
14.53M
9.69%
Spain
6.44M
4.29%
Mexico
6.23M
4.15%
Ireland
5.48M
3.65%
Other
1.06M
0.71%
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, May 17
Aktualisiert: Sat, May 17
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Frost Gamma Investments Trust
27.69%
Rubric Capital Management LP
6.02%
Holbrook (Bruce C)
5.09%
Hsiao (Jane H)
4.17%
Frost Group, L.L.C.
3.80%
Other
53.23%
Aktionäre
Aktionäre
Anteil
Frost Gamma Investments Trust
27.69%
Rubric Capital Management LP
6.02%
Holbrook (Bruce C)
5.09%
Hsiao (Jane H)
4.17%
Frost Group, L.L.C.
3.80%
Other
53.23%
Aktionärstypen
Aktionäre
Anteil
Corporation
36.58%
Hedge Fund
12.09%
Investment Advisor
10.34%
Individual Investor
10.23%
Investment Advisor/Hedge Fund
6.18%
Research Firm
1.84%
Bank and Trust
0.16%
Sovereign Wealth Fund
0.14%
Pension Fund
0.12%
Other
22.32%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
470
616.50M
77.74%
-1.20M
2025Q1
498
645.32M
88.41%
+25.74M
2024Q4
501
573.04M
84.80%
-7.63M
2024Q3
497
562.18M
81.01%
-12.00M
2024Q2
501
553.77M
79.70%
+8.59M
2024Q1
492
531.83M
76.52%
-21.84M
2023Q4
493
533.01M
69.65%
+31.42M
2023Q3
496
529.79M
69.24%
+23.70M
2023Q2
502
536.53M
70.13%
+25.42M
2023Q1
520
541.69M
71.63%
+67.95M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Frost Gamma Investments Trust
219.80M
27.72%
-26.90M
-10.90%
Apr 10, 2025
Rubric Capital Management LP
48.71M
6.14%
--
--
Mar 31, 2025
Holbrook (Bruce C)
40.38M
5.09%
--
--
Feb 24, 2025
Hsiao (Jane H)
33.13M
4.18%
--
--
Apr 02, 2025
Frost Group, L.L.C.
30.13M
3.8%
--
--
Apr 02, 2025
The Vanguard Group, Inc.
29.42M
3.71%
+293.74K
+1.01%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
24.77M
3.12%
-514.39K
-2.03%
Mar 31, 2025
GJN 2021 Trust
19.91M
2.51%
--
--
Feb 24, 2025
EGN 2021 Trust
19.91M
2.51%
--
--
Feb 24, 2025
Sculptor Capital Management, Inc
12.72M
1.6%
+12.72M
--
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
SPDR S&P Health Care Services ETF
0.69%
Invesco NASDAQ Future Gen 200 ETF
0.44%
Amplify Weight Loss Drug & Treatment ETF
0.22%
VanEck Israel ETF
0.14%
iShares U.S. Healthcare Providers ETF
0.09%
Humankind US Stock ETF
0.09%
Vanguard US Momentum Factor ETF
0.08%
Invesco RAFI US 1500 Small-Mid ETF
0.05%
iShares Biotechnology ETF
0.05%
iShares MSCI USA Small-Cap Min Vol Factor ETF
0.05%
Mehr Anzeigen
SPDR S&P Health Care Services ETF
Anteil0.69%
Invesco NASDAQ Future Gen 200 ETF
Anteil0.44%
Amplify Weight Loss Drug & Treatment ETF
Anteil0.22%
VanEck Israel ETF
Anteil0.14%
iShares U.S. Healthcare Providers ETF
Anteil0.09%
Humankind US Stock ETF
Anteil0.09%
Vanguard US Momentum Factor ETF
Anteil0.08%
Invesco RAFI US 1500 Small-Mid ETF
Anteil0.05%
iShares Biotechnology ETF
Anteil0.05%
iShares MSCI USA Small-Cap Min Vol Factor ETF
Anteil0.05%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
